Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma

被引：3
|
作者：
Schadendorf, Dirk
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ji, Ran
Aimone, Paola
Manson, Stephanie
Kefford, Richard
Dummer, Reinhard
Kirkwood, John M.
Long, Georgina V.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Fdn Ist Nazl Tumori, Milan, Italy
[4] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld 4072, Australia
[5] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[6] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Oslo, Norway
[9] Ctr Hosp Univ Bordeaux, Hop St Andre, Bordeaux, France
[10] Alfred Hosp, Melbourne, Australia
[11] Univ Lille, INSERM, U 1189, Lille, France
[12] Inst Gustave Roussy, Paris, France
[13] Sheba Med Ctr, Ella Inst Melanoma, Tel Hashomer, Israel
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis AG, Basel, Switzerland
[16] Macquarie Univ, Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia
[17] Univ Sydney, Sydney, NSW, Australia
[18] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland
[19] Univ Pittsburgh, Melanoma Program, Hillman UPMC Canc Ctr, Pittsburgh, PA USA
[20] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[21] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9590
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM)
    Lee, Clara Inkyung
    Menzies, Alexander M.
    Haydu, Lauren
    Clements, Arthur
    Kefford, Richard
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Adjuvant dabrafenib plus trametinib (D plus T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
    Schadendorf, Dirk
    Hauschild, Axel
    Mandala, Mario
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    Nathan, Paul D.
    Davies, Michael A.
    Banerjee, Hiya
    Shah, Rohan
    Lau, Mike R.
    Dummer, Reinhard
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB plus TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL
    Alves, D.
    Amadi, A.
    Moshyk, A.
    Betts, K.
    Du, E. X.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [24] Five-year analysis on the long-term effects of dabrafenib plus trametinib (D plus T) in patients with BRAF V600-mutant unresectable or metastatic melanoma.
    Nathan, Paul D.
    Robert, Caroline
    Grob, Jean Jacques
    Stroyakovskiy, Daniil
    Karaszewska, Boguslawa
    Hauschild, Axel
    Levchenko, Eugeny
    Sileni, Vanna Chiarion
    Schachter, Jacob
    Garbe, Claus
    Bondarenko, Igor
    Davies, Michael A.
    Ribas, Antoni
    Flaherty, Keith
    Burgess, Paul
    Tan, Monique
    Gasal, Eduard
    Schadendorf, Dirk
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Effect of first-line spartalizumab plus dabrafenib plus trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma.
    Dummer, Reinhard
    Biette, Kelly
    Gusenleitner, Daniel
    Ramesh, Radha
    Lebbe, Celeste
    Atkinson, Victoria
    Mandala, Mario
    Nathan, Paul D.
    Arance, Ana
    Richtig, Erika
    Yamazaki, Naoya
    Robert, Caroline
    Schadendorf, Dirk
    Tawbi, Hussein Abdul-Hassan
    Ascierto, Paolo Antonio
    Ribas, Antoni
    Flaherty, Keith
    Gasal, Eduard
    Brase, Jan C.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T)
    Dummer, Reinhard
    Gusenleitner, Daniel
    Campbell, Catarina D.
    Lebbe, Celeste
    Atkinson, Victoria
    Mandala, Mario
    Nathan, Paul D.
    Arance, Ana
    Richtig, Erika
    Yamazaki, Naoya
    Robert, Caroline
    Schadendorf, Dirk
    Tawbi, Hussein Abdul-Hassan
    Ascierto, Paolo Antonio
    Ribas, Antoni
    Flaherty, Keith
    Gasal, Eduard
    Brase, Jan C.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [27] Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
    Dummer, Reinhard
    Gusenleitner, Daniel
    Campbell, Catarina D.
    Lebbe, Celeste
    Atkinson, Victoria
    Mandala, Mario
    Nathan, Paul D.
    Arance, Ana
    Richtig, Erika
    Yamazaki, Naoya
    Robert, Caroline
    Schadendorf, Dirk
    Tawbi, Hussein Abdul-Hassan
    Ascierto, Paolo Antonio
    Ribas, Antoni
    Flaherty, Keith
    Gasal, Eduard
    Brase, Jan C.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
    Dummer, Reinhard
    Brase, Jan C.
    Garrett, James
    Campbell, Catarina D.
    Gasal, Eduard
    Squires, Matthew
    Gusenleitner, Daniel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    Flaherty, Keith
    Larkin, James
    Robert, Caroline
    Kefford, Richard
    Kirkwood, John M.
    Hauschild, Axel
    Schadendorf, Dirk
    Long, Georgina, V
    LANCET ONCOLOGY, 2020, 21 (03): : 358 - 372
  • [29] Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)
    Cella, D.
    Bookman, M.
    Steffensen, K. Dahl
    Coleman, R. L.
    Dinh, M.
    Khandelwal, N.
    Benjamin, K.
    Kamalakar, R.
    Sullivan, D.
    Floden, L.
    Hudgens, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S612 - S612
  • [30] KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
    Ascierto, P. A.
    Ferrucci, P. F.
    Stephens, R.
    Del Vecchio, M.
    Atkinson, V.
    Schmidt, H.
    Schachter, J.
    Queirolo, P.
    Long, G. V.
    Di Giacomo, A. M.
    Svane, I.
    Lotem, M.
    Bar-Sela, G.
    Couture, F.
    Mookerjee, B. P.
    Ghori, R.
    Ibrahim, N.
    Moreno, B. Homet
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 442 - 442
12345